Studylib
Explore
Login
Upload document Create flashcards
Login
Flashcards Collections
Documents
Last activity
My documents
Saved documents
Profile
Språk efter land Matematik Vetenskap Samhällsvetenskap Näringsliv Ingenjörsvetenskap Arts & Humanities Historia
  1. Vetenskap
  2. Biologi
  3. Farmakologi
DC.title - Alfresco
DC.title - Alfresco
DC.title - Alfresco
DC.title - Alfresco
DC.title - Alfresco
DC.title - Alfresco
DC.title - Alfresco
DC.title - Alfresco
DC.title - Alfresco
DC.title - Alfresco
DB Pharma, Särläkemedelsstatus i hamn
DB Pharma, Särläkemedelsstatus i hamn
Daxas, INN-roflumilast
Daxas, INN-roflumilast
Daxas ingår i högkostnadsskyddet med generell subvention
Daxas ingår i högkostnadsskyddet med generell subvention
David Zideman
David Zideman
datum: 11-09-2014, v
datum: 11-09-2014, v
Datum - Region Örebro län
Datum - Region Örebro län
Datum - Region Halland
Datum - Region Halland
Datortomografi CT An Piteå sjukhus
Datortomografi CT An Piteå sjukhus
DASH3® ENFit
DASH3® ENFit
Darzalex, INN-daratumumab
Darzalex, INN-daratumumab
Darunavir STADA 600 mg film-coated tablet PL
Darunavir STADA 600 mg film-coated tablet PL
Darunavir STADA 600 mg film
Darunavir STADA 600 mg film
Darunavir STADA 400 mg and 800 mg film
Darunavir STADA 400 mg and 800 mg film
Darunavir STADA 400 mg and 800 mg film
Darunavir STADA 400 mg and 800 mg film
Darunavir Sandoz 800 mg film
Darunavir Sandoz 800 mg film
Darunavir Sandoz 75 mg and 600 mg film
Darunavir Sandoz 75 mg and 600 mg film
  • « prev
  • 1 ...
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • ... 448
  • » next
Products
Documents Flashcards
Support
Report Partners
© 2013 - 2025 studylibsv.com all other trademarks and copyrights are the property of their respective owners
Privacy Terms

Make a suggestion

Did you find mistakes in interface or texts? Or do you know how to improve StudyLib UI? Feel free to send suggestions. Its very important for us!

 

Suggest us how to improve StudyLib

(For complaints, use another form )

Input it if you want to receive answer

Rate us